Loading stock data…
Intellia Therapeutics, Inc. (NTLA)
$10.73-0.37 (-3.33%)
Market ClosedLast close Jul 24
Intellia Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Intellia Therapeutics, Inc. in the Healthcare sector is trading at $10.73 with a market capitalization of $2.3B. Wall Street consensus targets $26.17 (18 analysts), implying a +143.9% move over the next 12 months. The stock is currently near its 52-week low of $7.95, remaining 19.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +143.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 9) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.05M↓ | $23.02M↑ | $13.78M↓ | $14.24M↓ | $16.63M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$100.53M↓ | -$98.71M↑ | -$111.48M↓ | -$110.00M↑ | -$120.81M |
| Net Income | -$96.23M↓ | -$95.79M↑ | -$101.32M | -$101.25M↑ | -$114.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-63.55%
Volume
Today's trading volume
3.35M
Recent News
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success
Why Intellia Therapeutics Stock Is Back in Focus Intellia Therapeutics (NTLA) is back on investors’ radar after announcing successful Phase 3 trial results for its gene editing treatment Lonvo-z and outlining plans for a future U.S. launch. These clinical milestones mark a clear step toward potential commercialization and broader market reach. This has coincided with renewed interest in Intellia Therapeutics stock performance and valuation in recent months. See our latest analysis for...
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns
Intellia Therapeutics has staged a sharp rebound in 2026, yet its long term track record and current valuation checks suggest the stock may still be priced with little room for disappointment. The recent surge around its in vivo CRISPR program sits against a weaker 5 year return profile and a low value score. Over the past 5 years, Intellia Therapeutics has delivered a decline of 88.1%, which puts the recent recovery into context as a rebound rather than a clear long term win so far. The...
Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears
WOLF is now Wall Street's most shorted stock. Here's why bears keep piling on even after Wolfspeed's big debt overhaul.